As we look ahead to 2026, SynAct Pharma is summing up a year marked by a broadened pipeline, increased ambitions and a strengthened financial position. In an interview with BioStock, CEO Jeppe Øvlesen and CBO Mads Bjerregaard talk about where the company stands at the end of 2025, how the pipeline and business development work is progressing, and what milestones and opportunities may characterise the coming year.
See the interview with SynAct Pharma CEO Jeppe Øvelsen and CBO Mads Bjerregaard, in English, below.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.